Efmoroctocog alfa - Bioverativ/Swedish Orphan Biovitrum
Alternative Names: Antihaemophilic factor VIII (recombinant), Fc fusion protein; BIIB-031; Efmoroctocog alfa; Efraloctocog alfa; Elocta; Eloctate; Factor VIII-Fc; FVIII-Fc; Long-lasting factor VIII fusion protein; Recombinant factor VIII Fc; Recombinant factor VIII Fc fusion protein; rFVIII-FcLatest Information Update: 06 Feb 2024
At a glance
- Originator Syntonix Pharmaceuticals
- Developer Bioverativ; Swedish Orphan Biovitrum; Syntonix Pharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 31 Jan 2024 Launched for Haemophilia A in New Zealand (IV)
- 05 Dec 2020 Final efficacy and adverse events data from the phase III PUPs A-LONG trial in Heamophilia A presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
- 13 Jul 2020 Safety and efficacy data from the phase III PUPs A-LONG trial in Haemophilia A released by Sobi and Sanofi